Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

Completed · Phase 1 · Has a placebo group

Conditions studied: Non-Alcoholic Steatohepatitis

In brief

This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.

Key facts

Study ID

NCT02287779

Run by

Mirum Pharmaceuticals, Inc.

People needed

84

Starts

2015-01-19

Expected to finish

2015-06-19

Last updated by the study team

2019-03-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Males that comply with any applicable contraceptive requirements or females of non-childbearing potential
• No history of active or chronic disease other than that allowed by study (hypertension, hyperlipidemia and GERD or heartburn)
• Has a body mass index of 25-35 kg/m2 with a body weight of greater than 140lbs (assessed at screening)

You may not qualify if…

• No history of alcohol or substance abuse, including use of tobacco
• No substantial changes in eating habits or exercise routine.

Where it is running

• New Orleans Center for Clinical Research — Knoxville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.